fbpx

Nyheder

Lundbeckfonden Ventures nyheder

. Collaboration to leverage Syntaxin and Ipsen’s expertise in the discovery and development of botulinum toxins   Paris (France) and Oxford (UK), 20 October 2011 – Ipsen (Euronext: IPN, ADR: IPSEY) and Syntaxin, a biotechnology company specialising in innovative biopharmaceutical therapies targeting cell secretion pathways, announced today a global strategic collaboration to explore the discovery...
The Swedish MedTech company BoneSupport is implementing a follow-up share issue with the Danish investment fund Lundbeckfond Ventures. Together with the share issue in June this year, the company has raised totally 170 MSEK during 2011. The company markets CERAMENT T, an injectable biologic that remodels into bone and heals fractures. The raised capital will...
Download press release here: Acacia_Pharma_starts_Phase_II_clinical_trail_f.PDF
The U.S. Food and Drug Administration has granted 510(k) clearance for Asante Solutions' Pearl Insulin Pump. ASANTE_press_release_051711.pdf
DBV demonstrates ability of VIASKIN® to administer allergen via intact skin by targeting dendrictic cells for safe treatment of allergic disease. News_J_Immunol.pdf
Syntaxin enters manufacturing agreement with SynCo Bio Partners B.V. Progresses Acromegaly programme towards clinic. SynCo_Bio_Release_9_5_2011_(2).pdf
Funds to be used to complete two Phase II programmes
1 45 46 47 48

Lundbeckfonden Ventures

Nyheder

Spero Therapeutics Announces FDA Acceptance of IND Application for SPR994
4. februar 2019
BONESUPPORT and Lund University to present at Orthopaedic Research Society (ORS) 2019 Annual Meeting
1. februar 2019
scPharmaceuticals Inc. Announces Development Agreement with West Pharmaceutical Services for Next-Generation FUROSCIX® On-Body Infusor
29. januar 2019